Last week, the Journal of Thoracic Oncology published the results of a study looking into the overexpression of the ephrin B2 receptor (EPHB2) in patients with mesothelioma. The researchers at the New York University Langone Medical Center observed that EPHB2 is overexpressed in all malignant mesothelioma cell lines, but not in benign mesothelial cells. In addition, […]
Research, Science and Treatments
Personalized medicine is the ability to select a biologic target and direct therapy against this target. It is associated with improved outcomes in a number of tumor types. The most startling was the development of Gleevec which targets CKit in gastrointestinal stromal tumors. The field has since grown by leaps and bounds. We are making […]
By Lee Krug, MD, Memorial Sloan-Kettering Cancer Center
The American Society of Clinical Oncology meeting was held from June 1-4 in Chicago. This is the largest oncology meeting each year with around 30,000 attendees from all over the globe who congregate to discuss the latest research in all cancer types. I thought I would summarize a […]
BAP1 is the first gene discovered in mesothelioma. Not everyone has the mutated copy of this gene and, in fact, we are just embarking on trials to try to get a better handle on the incidence.
In germ line mutations (inherited mutation), the gene is thought to be extremely rare but has some interesting associations with […]
Every year, consumers spend an estimated $40 billion on complementary and alternative medicine treatments and products, with hopes of miraculous cures, often unsupported by research or by science. Some consumers affected by life-threatening illnesses, including cancer, may approach the topic of supplements or alternative therapies as an added bonus without considering the side-effects or the […]